Results 191 to 200 of about 26,462 (230)

P2Y12 receptors: structure and function

Journal of Thrombosis and Haemostasis, 2015
The platelet P2Y12 receptor (P2Y12R) for adenosine 5'diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild-to-moderate bleeding diatheses. Defects of P2Y12R should be suspected when ADP, even at high concentrations (≥ 10 μm), is unable to induce full, irreversible ...
openaire   +3 more sources

P2Y12 receptor inhibition and LPS-induced coagulation

Clinical Science, 2016
Platelets play a major role in the complex interactions involved in blood coagulation via multiple mechanisms. As reported in this issue, Schoergenhofer et al. tested the hypothesis that platelet inhibition by prasugrel, a potent platelet P2Y12 ADP receptor antagonist, attenuates the effect of lipopolysaccharide (LPS) on the blood coagulation system in
David W, Essex, A Koneti, Rao
openaire   +2 more sources

Responsiveness to P2Y12 receptor inhibitors

Current Opinion in Cardiology, 2011
This review is aimed at describing the variability in response to P2Y12 inhibitor agents, and to focus on the main tests currently available to assess the responsiveness.There is high interindividual response variability to clopidogrel. Some patients do not respond to the drug; this condition can be due to patient-related factors (poor compliance ...
openaire   +3 more sources

Strategies for targeting the P2Y12 receptor in the central nervous system

Bioorganic & Medicinal Chemistry Letters, 2022
The purinergic 2Y type 12 receptor (P2Y12R) is a well-known biological target for anti-thrombotic drugs due to its role in platelet aggregation and blood clotting. While the importance of the P2Y12R in the periphery has been known for decades, much less is known about its expression and roles in the central nervous system (CNS), where it is expressed ...
Ben B, Ma, Andrew P, Montgomery, Biling, Chen, Michael, Kassiou, Jonathan J, Danon   +4 more
openaire   +2 more sources

Biology and Pharmacology of the Platelet P2Y12 Receptor

Current Pharmaceutical Design, 2006
Platelets possess two receptors for ADP, P2Y(1) and P2Y(12). ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus. The P2Y(1) receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation.
openaire   +2 more sources

Microglia modulate general anesthesia through P2Y12 receptor

Current Biology, 2023
General anesthesia (GA) is an unconscious state produced by anesthetic drugs, which act on neurons to cause overall suppression of neuronal activity in the brain. Recent studies have revealed that GA also substantially enhances the dynamics of microglia, the primary brain immune cells, with increased process motility and territory surveillance. However,
Kelei Cao, Liyao Qiu, Xuan Lu, Weiying Wu, Yaling Hu, Zhicheng Cui, Chao Jiang, Yuxiang Luo, Yujin Shao, Wang Xi, Ling-Hui Zeng, Han Xu, Huan Ma, Zhi Zhang, Jiyun Peng, Shumin Duan, Zhihua Gao   +16 more
openaire   +2 more sources

P2Y12 receptor: platelet thrombus formation and medical interventions

International Journal of Hematology, 2012
Platelets express a wide range of receptors and proteins that play essential roles in thrombus formation. Among these, the P2Y(12) receptor, a member of the G protein-coupled receptor family, has attracted a significant amount of attention. Stimulation of the P2Y(12) receptor by ADP results in activation of various signaling pathways involved in ...
Fatemeh Moheimani
exaly   +4 more sources

Switching Platelet P2Y12 Receptor Inhibiting Therapies

Interventional Cardiology Clinics
Antiplatelet therapy involving aspirin and a P2Y12 receptor inhibitor is fundamental in managing patients with atherothrombotic disease. Switching between P2Y12 inhibitors is frequently observed in clinical settings for various reasons, such as safety, efficacy, patient adherence, or cost concerns.
Luis, Ortega-Paz, Fabiana, Rollini, Francesco, Franchi, Dirk, Sibbing, Dominick J, Angiolillo   +4 more
openaire   +2 more sources

Decreased platelet inhibition by P2Y12 receptor blockers in anaemia

European Journal of Clinical Investigation, 2017
AbstractBackgroundAnaemic patients undergoing angioplasty and stenting are at an increased risk of ischaemic events, which may be caused by an inadequate response to antiplatelet therapy with adenosine diphosphate (ADP) P2Y12 inhibitors. In the current study, we investigated the associations between anaemia and on‐treatment platelet reactivity in ...
Patricia P. Wadowski, Christoph W. Kopp, Renate Koppensteiner, Irene M. Lang, Joseph Pultar, Silvia Lee, Constantin Weikert, Simon Panzer, Thomas Gremmel   +8 more
openaire   +2 more sources

Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists

Clinical Pharmacokinetics, 2020
Coronary artery disease remains the major cause of mortality worldwide. Antiplatelet drugs such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for the prevention of thrombotic events in patients with coronary artery disease.
Uta Schilling, Jasper Dingemanse, Mike Ufer   +2 more
openaire   +2 more sources